NewAmsterdam Pharma Company NV. (NAMS) NASDAQ
$20.03 (0.03) (-0.12%)
Market Cap: $1.80B
As of 05/17/24 12:21 PM EDT. Market open.
NewAmsterdam Pharma Company NV. (NAMS)
NASDAQ
$20.03
(0.03) (-0.12%)
Market Cap: $1.80B
As of 05/17/24 12:21 PM EDT. Market open.
Add to Portfolio
... read more
COMPANY PROFILE
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
URL
Address
.
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
URL
Address
.
PRICE CHART FOR NEWAMSTERDAM PHARMA COMPANY NV
From:
To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$20.44
Previous Close
$20.05
Days Range
$19.79 - $20.45
52 week range
$5.63 - $26.35
Volume
60,094
Avg. Volume (30 days)
129,841
Market Cap
$1.80B
Dividend Yield
-
P/E
-
Shares Outstanding
89,976,538
Open
$20.44
Previous Close
$20.05
Days Range
$19.79 - $20.45
52 week range
$5.63 - $26.35
Volume
60,094
Avg. Volume (30 days)
129,841
Market Cap
$1.80B
Dividend Yield
-
P/E
-
Shares Outstanding
89,976,538
FINANCIAL STATEMENTS FOR NEWAMSTERDAM PHARMA COMPANY NV
LOADING...
Open in: 
Open in:
INSIDER TRANSACTIONS FOR NEWAMSTERDAM PHARMA COMPANY NV
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| Topper James N | Director | Mar 26, 2024 | Buy | $21.50 | 8,429 | 181,224 | 3,008,429 | Mar 28, 2024, 04:30 PM |
| Kastelein Johannes Jacob Pieter | Chief Scientific Officer | Mar 26, 2024 | Option Exercise | $22.72 | 11,197 | 254,396 | 190,476 | Mar 27, 2024, 04:30 PM |
| Kastelein Johannes Jacob Pieter | Chief Scientific Officer | Mar 26, 2024 | Sale | $21.50 | 190,476 | 4,095,234 | 0 | Mar 27, 2024, 04:30 PM |
| LANGE LOUIS G | Director | Feb 13, 2024 | Buy | $19.00 | 5,000 | 95,000 | 24,878 | Feb 21, 2024, 05:00 PM |
Buy
Sale
Option Exercise
| Owner | Relationship | Date | Value($) |
| Topper James N | Director | 03/26/2024 | 181,224 |
| Kastelein Johannes Jacob Pieter | Chief Scientific Officer | 03/26/2024 | 254,396 |
| Kastelein Johannes Jacob Pieter | Chief Scientific Officer | 03/26/2024 | 4,095,234 |
| LANGE LOUIS G | Director | 02/13/2024 | 95,000 |
FUNDS WITH A POSITION IN NEWAMSTERDAM PHARMA COMPANY NV
| Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
|---|---|---|---|---|
| VIKING GLOBAL INVESTORS LP | 8,024,565 | 0.71% | No change | Growth At A Reasonable Price |
| RA CAPITAL MANAGEMENT, L.P. | 7,864,000 | 2.38% | No change | Other |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 1,824,601 | 0.08% | 40.35% | Other |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 667,000 | 0.27% | New | Other |
| BAKER BROS. ADVISORS LP | 96,827 | 0.03% | New | Other |
| GEODE CAPITAL MANAGEMENT, LLC | 52,185 | 0.00011% | 10.27% | Other |
| BLACKROCK INC. | 11,220 | 0.00001% | -51.09% | Other |
| DUPONT CAPITAL MANAGEMENT CORP | 1 | 0% | No change | Other |
CHANGE IN SHARES OUTSTANDING FOR NEWAMSTERDAM PHARMA COMPANY NV
STOCK BUYBACKS FOR NEWAMSTERDAM PHARMA COMPANY NV
Period of Report: 12/31/2023
10-K/10-Q Filings: View
Previous Period
% Change in Shares
Quarter
06/30/2023
19.36%
2Q
12/31/2022
25.32%
4Q
BUYBACK ANNOUNCEMENT(S) FOR NEWAMSTERDAM PHARMA COMPANY NV
LOADING...